```
=> d his nofile


     FILE 'REGISTRY' ENTERED AT 12:17:03 ON 05 JUN 2007
                ACT SHOBHA/A
               ---------
L1               STR
L2            44 SEA SSS FUL L1
               ---------
L3            42 SEA ABB=ON  PLU=ON  L2 AND C5/ES

     FILE 'CAPLUS' ENTERED AT 12:26:00 ON 05 JUN 2007
L4            22 SEA ABB=ON  PLU=ON  L3

=> d que stat l3
L1               STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  12

STEREO ATTRIBUTES: NONE
L2            44 SEA FILE=REGISTRY SSS FUL L1
L3            42 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND C5/ES


=> fil reg
FILE 'REGISTRY' ENTERED AT 12:26:42 ON 05 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    4 JUN 2007  HIGHEST RN 936539-19-4
DICTIONARY FILE UPDATES:   4 JUN 2007  HIGHEST RN 936539-19-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.
```

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que stat l3
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L2 44 SEA FILE=REGISTRY SSS FUL L1
L3 42 SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND C5/ES

=> fil caplus
FILE 'CAPLUS' ENTERED AT 12:26:52 ON 05 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 5 Jun 2007 VOL 146 ISS 24
FILE LAST UPDATED: 4 Jun 2007 (20070604/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que nos l4

```
L1              STR
L2          44 SEA FILE=REGISTRY SSS FUL L1
L3          42 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND C5/ES
L4          22 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3


=> d ed .ca hitstr l4 1-22

L4   ANSWER 1 OF 22  CAPLUS  COPYRIGHT 2007 ACS on STN
ED   Entered STN:  04 Jan 2007
ACCESSION NUMBER:        2007:11789  CAPLUS  Full-text
DOCUMENT NUMBER:         146:121989
TITLE:                   Preparation of 1,4-dihydro-2H-3,1-benzoxazin-2-ones
                         and related compounds for the treatment of respiratory
                         diseases
INVENTOR(S):             Konetzki, Ingo; Bouyssou, Thierry; Pestel, Sabine;
                         Schnapp, Andreas
PATENT ASSIGNEE(S):      Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.,
                         Germany
SOURCE:                  Ger. Offen., 74pp.
                         CODEN: GWXXBX
DOCUMENT TYPE:           Patent
LANGUAGE:                German
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     DE 102005030733       A1    20070104    DE 2005-102005030733    20050701
     US 2007037781         A1    20070215    US 2006-424558          20060616
     WO 2007003554         A1    20070111    WO 2006-EP63650         20060628
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
             KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
             MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
             SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
             US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                   DE 2005-102005030733A  20050701
OTHER SOURCE(S):         MARPAT 146:121989
ED   Entered STN:  04 Jan 2007
GI
```



I



II

AB Title compds. I [Y = CRaRb(CH2)n; V = CH2, NH, O; X = O, NH, CH2O, etc.; Ra, Rb = H, alkyl, haloalkyl; R1, R1' = H, alkyl, cycloalkyl, etc.; R2, R2', R2'', R2''' = H, alkyl, OH, etc.; n = 0-2] and their pharmaceutically acceptable salts and formulations were prepared For example, dihydrobenzoxazinone II was prepared from 2-amino-5-methoxyacetophenone in 5-steps. Of note is the combination of compds. I with long-acting beta-2-agonists for treatment of respiratory diseases.

CC 28-18 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 50-02-2, Dexamethasone 50-24-8, Prednisolone 53-03-2, Prednison 56-14-4, Succinate, biological studies 58-55-9, Theophyllin 64-17-5, Ethanol, biological studies 71-50-1, Acetate, biological studies 74-98-6, n-Propane, biological studies 75-28-5, Isobutane 75-75-2, Methanesulfonic acid 106-97-8, n-Butane, biological studies 124-94-7, Triamcinolon 126-44-3, Citrate, biological studies 142-42-7, Fumarate, biological studies 142-44-9, biological studies 144-62-7, Ethanedioic acid, biological studies 431-89-0, TG227 766-76-7, Benzoate, biological studies 811-97-2, TG134a 3385-03-3, Flunisolide 3715-17-1, Tartrate, biological studies 4419-39-0, Beclomethasone 14265-44-2, Phosphate, biological studies 14797-55-8, Nitrate, biological studies 16722-51-3, p-Toluenesulfonate, biological studies 16887-00-6, Chloride, biological studies 16984-48-8, Fluoride, biological studies 20461-54-5, Iodide, biological studies 24959-67-9, Bromide, biological studies 41078-02-8, Enprofylline 51333-22-3, Budesonide 87454-84-0, TG11 90566-53-3, Fluticasone 98449-05-9, Butixocortpropionate 103177-37-3, Pranlukast 105102-22-5, Mometasone 107753-78-6, Zafirlukast 125961-82-2, MN 001 126544-47-6, Ciclesonide 135637-46-6, Atizoram 136145-07-8, Arofylline 144459-70-1, Rofleponide 146426-61-1 149413-74-1, [2-[[[2-(4-tert-Butylthiazol-2-yl)benzofuran-5-yl]oxy]methyl]phenyl]acetic acid 153259-65-5, Ariflo 153587-17-8, 2-Carbomethoxy-4-cyano-4-(3-((cyclopropyl)methoxy)-4-difluoromethoxyphenyl)cyclohexan-1-one 154284-39-6, cis-4-Cyano-4-(3-((cyclopropyl)methoxy)-4-difluoromethoxyphenyl)cyclohexan-1-ol 155043-84-8, T-440 159001-35-1, RPR-106541 162278-09-3, V-11294A 162401-32-3, Roflumilast 162542-90-7, CDP840 179024-48-7, PD 168787 180288-69-1, Trastuzumab 182282-60-6, D-22888 183321-74-6, 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline **185954-27-2**, 9-Cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine **185954-42-1**,

9-Cyclopentyl-5,6-dihydro-7-ethyl-3-(tert-butyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine 186461-26-7, T 2585 187724-61-4 190377-71-0, NCS 613 192056-77-2 192819-27-5, CDC-801 197506-04-0, MEN-91507 199331-40-3 205923-56-4, Cetuximab 207993-12-2, BY 343 231277-92-2, 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline 257892-33-4, AWD-12-281 257892-34-5, D-4418 267243-28-7, 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline 292135-78-5, N-(3,5-Dichloro-1-oxopyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide 314771-10-3, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-cyclopropylmethoxyquinazoline 314771-31-8, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino]-7-cyclopropylmethoxyquinazoline 326894-84-2, 3-Cyano-4-[(3-chloro-4-fluorophenyl)amino]-6-[[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-ethoxyquinoline 329306-27-6, Bay-19 8004 339177-26-3, ABXEGF 397864-44-7 402569-98-6 402573-59-5, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[2-[4-(2-oxomorpholin-4-yl)piperidin-1-yl]ethoxy]-7-methoxyquinazoline 402734-20-7 402735-03-9 402735-06-2, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[2-(2,2-dimethyl-6-oxomorpholin-4-yl)ethoxy]-7-methoxyquinazoline 402735-09-5 402855-53-2 402855-58-7 402855-61-2 438245-34-2, ST-126 439081-10-4, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino]-7-cyclopentyloxyquinazoline 439081-11-5 439081-12-6 439081-13-7 439081-14-8 439081-17-1 439081-18-2 439081-24-0, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[4-[N,N-bis(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl]amino]-7-[(tetrahydrofuran-2-yl)methoxy]quinazoline 439081-25-1, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino]-7-[(tetrahydrofuran-2-yl)methoxy]quinazoline 439081-26-2, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[4-[N-(2-methoxyethyl)-N-methylamino]-1-oxo-2-buten-1-yl]amino]-7-cyclopentyloxyquinazoline 439081-30-8, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[4-(N-cyclopropyl-N-methylamino)-1-oxo-2-buten-1-yl]amino]-7-cyclopentyloxyquinazoline 439081-39-7 439081-40-0 439081-48-8, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[4-[N-(2-methoxyethyl)-N-methylamino]-1-oxo-2-buten-1-yl]amino]-7-cyclopropylmethoxyquinazoline 444659-35-2, YM 58997 444659-43-2, Sch-351591 458567-90-3, CP 325 458569-01-2, TG 12 573649-57-7, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]amino]-7-cyclopropylmethoxyquinazoline 573649-59-9 609767-43-3, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[(1-(tert-butyloxycarbonyl)piperidin-4-yl)oxy]-7-methoxyquinazoline 609767-45-5, 4-[(3-Chloro-4-fluorophenyl)amino]-6-((1-methylpiperidin-4-yl)oxy)-7-methoxyquinazoline 609767-47-7 609767-50-2 609767-51-3, 4-[(3-Chloro-4-fluorophenyl)amino]-6-((1-(methanesulfonyl)piperidin-4-yl)oxy)-7-methoxyquinazoline 609767-56-8, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[1-[(morpholin-4-yl)carbonyl]piperidin-4-yl]oxy]-7-methoxyquinazoline 609767-57-9, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[1-[(methoxymethyl)carbonyl]piperidin-4-yl]oxy]-7-methoxyquinazoline 609767-58-0, 4-[(3-Chloro-4-fluorophenyl)amino]-6-(1-cyanopiperidin-4-yloxy)-7-methoxyquinazoline 610302-28-8, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[1-(2-acetylaminoethyl)piperidin-4-yl]oxy]-7-methoxyquinazoline 610302-29-9, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[trans-4-[((dimethylamino)sulfonyl)amino]cyclohexan-1-yl]oxy]-7-methoxyquinazoline 610302-30-2, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[trans-4-[((morpholin-4-yl)carbonyl)amino]cyclohexan-1-yl]oxy]-7-methoxyquinazoline 610302-31-3, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[trans-4-[((morpholin-4-yl)sulfonyl)amino]cyclohexan-1-yl]oxy]-7-methoxyquinazoline 610302-54-0, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[1-[(piperidin-1-yl)carbonyl]piperidin-4-yloxy]-7-methoxyquinazoline 610302-58-4, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[cis-4-(N-

methanesulfonyl-N-methylamino)cyclohexan-1-yl]oxy]-7-methoxyquinazoline 610302-60-8, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[cis-4-(N-acetyl-N-methylamino)cyclohexan-1-yl]oxy]-7-methoxyquinazoline 610302-62-0, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[cis-4-[N-(2-methoxyacetyl)-N-methylamino]cyclohexan-1-yl]oxy]-7-methoxyquinazoline 610302-66-4, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[cis-4-[N-[(morpholin-4-yl)carbonyl]-N-methylamino]cyclohexan-1-yl]oxy]-7-methoxyquinazoline 610302-68-6, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[cis-4-[N-[(morpholin-4-yl)sulfonyl]-N-methylamino]cyclohexan-1-yl]oxy]-7-methoxyquinazoline 610302-72-2, 4-[(3-Chloro-4-fluorophenyl)amino]-6-((trans-4-(((ethane)sulfonyl)amino)cyclohexan-1-yl)oxy)-7-methoxyquinazoline 610302-76-6, 4-[(3-Chloro-4-fluorophenyl)amino]-6-(1-methanesulfonylpiperidin-4-yloxy)-7-ethoxyquinazoline 610302-82-4, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[1-[(morpholin-4-yl)carbonyl]piperidin-4-yloxy]-7-(2-methoxyethoxy)quinazoline 610302-83-5, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[1-(2-methoxyacetyl)piperidin-4-yl]oxy]-7-(2-methoxyethoxy)quinazoline 610302-84-6 610302-86-8, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[cis-4-[N-[(piperidin-1-yl)carbonyl]-N-methylamino]cyclohexan-1-yl]oxy]-7-methoxyquinazoline 610302-87-9, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[cis-4-[N-[(4-methylpiperazin-1-yl)carbonyl]-N-methylamino]cyclohexan-1-yl]oxy]-7-methoxyquinazoline 610302-89-1, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[cis-4-[((morpholin-4-yl)carbonyl)amino]cyclohexan-1-yl]oxy]-7-methoxyquinazoline 610302-91-5, 4-[(3-Ethynylphenyl)amino]-6-(1-acetylpiperidin-4-yloxy)-7-methoxyquinazoline 610302-92-6, 4-[(3-Ethynylphenyl)amino]-6-[[1-(2-methoxyacetyl)piperidin-4-yl]oxy]-7-methoxyquinazoline 610302-93-7, 4-[(3-Ethynylphenyl)amino]-6-(1-methanesulfonylpiperidin-4-yloxy)-7-methoxyquinazoline 610302-94-8, 4-[(3-Ethynylphenyl)amino]-6-[1-[(morpholin-4-yl)carbonyl]piperidin-4-yloxy]-7-methoxyquinazoline 610302-96-0, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[trans-4-(N-methanesulfonyl-N-methylamino)cyclohexan-1-yl]oxy]-7-methoxyquinazoline 610302-97-1, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[trans-4-[N-[(morpholin-4-yl)carbonyl]-N-methylamino]cyclohexan-1-yl]oxy]-7-methoxyquinazoline 610303-35-0, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[cis-4-[N-[(tetrahydropyran-4-yl)carbonyl]-N-methylamino]cyclohexan-1-yl]oxy]-7-methoxyquinazoline 610303-39-4, 4-[(3-Chloro-4-fluorophenyl)amino]-6-(1-methylpiperidin-4-yloxy)-7-(2-methoxyethoxy)quinazoline 610303-41-8, 4-[(3-Chloro-4-fluorophenyl)amino]-6-((trans-4-dimethylaminocyclohexan-1-yl)oxy)-7-methoxyquinazoline 610303-42-9, 4-[(3-Ethynylphenyl)amino]-6-[[1-(tert-butyloxycarbonyl)piperidin-4-yl]oxy]-7-methoxyquinazoline 625853-93-2, ICR 62 646070-23-7, MCC 847 646070-38-4, VUF-K 8707 760171-44-6, 4-[(3-Chloro-4-fluorophenyl)amino]-6-((piperidin-3-yl)oxy)-7-methoxyquinazoline 774180-32-4, 4-[(3-Ethynylphenyl)amino]-6-(1-methylpiperidin-4-yloxy)-7-methoxyquinazoline 835882-98-9 835882-99-0 836652-75-6, C 1-1018 836652-82-5, CDC 3052 836652-83-6, Z 15370 840541-73-3, 4-[(3-Chloro-4-fluorophenyl)amino]-6-((trans-4-methylaminocyclohexan-1-yl)oxy)-7-methoxyquinazoline 840541-77-7 850795-59-4, 4-[(3-Chloro-4-fluorophenyl)amino]-6-(1-aminocarbonylmethylpiperidin-4-yloxy)-7-methoxyquinazoline 850795-60-7, 4-[(3-Chloro-4-fluorophenyl)amino]-6-(1-methanesulfonylpiperidin-4-yloxy)-7-(2-methoxyethoxy)quinazoline 850795-61-8, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[1-[2-(2-oxopyrrolidin-1-yl)ethyl]piperidin-4-yl]oxy]-7-methoxyquinazoline 850795-62-9, 4-[(3-Chloro-4-fluorophenyl)amino]-6-(1-isopropyloxycarbonylpiperidin-4-yloxy)-7-methoxyquinazoline 850795-63-0 850795-64-1 850795-65-2, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[1-[(2-methylmorpholin-4-yl)carbonyl]piperidin-4-yloxy]-7-methoxyquinazoline 850795-66-3 850795-67-4, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[[1-[(N-methyl-N-(2-methoxyethyl)amino)carbonyl]piperidin-4-yl]oxy]-7-methoxyquinazoline

850795-68-5, 4-[(3-Chloro-4-fluorophenyl)amino]-6-(1-ethylpiperidin-4-yloxy)-7-methoxyquinazoline 850795-69-6, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[1-[(2-methoxyethyl)carbonyl]piperidin-4-yloxy]-7-methoxyquinazoline 850795-70-9, 4-[(3-Chloro-4-fluorophenyl)amino]-6-[1-[(3-methoxypropylamino)carbonyl]piperidin-4-yloxy]-7-methoxyquinazoline 868157-47-5, VUF 5078 868157-48-6, L 733321 918499-28-2 918499-29-3, 4-[(3-Chloro-4-fluorophenyl)amino]-6-(tetrahydropyran-3-yloxy)-7-methoxyquinazoline 918499-30-6 918499-31-7 918499-32-8 918499-34-0 918499-38-4, 4-[(3-Ethynylphenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-methoxyquinazoline 918499-39-5, 4-[(3-Ethynylphenyl)amino]-6-(piperidin-4-yloxy)-7-methoxyquinazoline
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicaments with; preparation of 1,4-dihydro-2H-3,1-benzoxazin-2-ones and related compds. for the treatment of respiratory diseases)

IT **185954-27-2**, 9-Cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine **185954-42-1**, 9-Cyclopentyl-5,6-dihydro-7-ethyl-3-(tert-butyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicaments with; preparation of 1,4-dihydro-2H-3,1-benzoxazin-2-ones and related compds. for the treatment of respiratory diseases)

RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



L4 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 22 Dec 2006
ACCESSION NUMBER: 2006:1339527 CAPLUS Full-text
DOCUMENT NUMBER: 146:87582
TITLE: MRP4 inhibitors for the treatment of respiratory diseases
INVENTOR(S): Goeggel, Rolf; Cui, Yunhai
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG

SOURCE: PCT Int. Appl., 63pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006134022	A1	20061221	WO 2006-EP62690	20060530
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006286041	A1	20061221	US 2006-424596	20060616
PRIORITY APPLN. INFO.:			EP 2005-105363 A	20050617

OTHER SOURCE(S): MARPAT 146:87582
ED Entered STN: 22 Dec 2006
AB The present invention relates to the use of MRP4 inhibitors for the treatment of respiratory diseases, pharmaceutical compns. containing them and processes for the preparation thereof.
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 2
IT 58-55-9, Theophyllin 41078-02-8, Enprofylline 135637-46-6, Atizoram 136145-07-8, Arofylline 145739-56-6, Tetomilast 146426-61-1, (R)-(+)-1-(4-Bromobenzyl)-4-[(3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidone 146426-68-8 153259-65-5, Cilomilast 153587-17-8 153587-23-6 155043-84-8, T-440 162278-09-3, V-11294A 162401-32-3, Roflumilast 162542-90-7, CDP840 179024-48-7, PD 168787 182282-60-6, D-22888 **185954-27-2 185954-42-1**, 9-Cyclopentyl-5,6-dihydro-7-ethyl-3-(tert-butyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine 186461-26-7, T 2585 190377-71-0, NCS 613 192819-27-5, CDC-801 207993-12-2, BY 343 245329-99-1, CI 1018 257892-33-4, AWD-12-281 257892-34-5, D-4418 292135-78-5 329306-27-6, Bay 19-8004 444659-35-2, YM 58997 444659-43-2, D-4396 478409-36-8, CP 325366 835882-98-9 835882-99-0 836652-82-5, CDC 3052 836652-83-6, Z 15370 916057-21-1, 4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-(1-hydroxyethyl)-3-methylpyrrolidine-1-carboxylic acid methyl ester
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PDE-IV inhibitor; MRP4 inhibitors in combination with other therapeutic agents for treatment of respiratory diseases)
IT **185954-27-2 185954-42-1**, 9-Cyclopentyl-5,6-dihydro-7-ethyl-3-(tert-butyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PDE-IV inhibitor; MRP4 inhibitors in combination with other therapeutic agents for treatment of respiratory diseases)
RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 20 Dec 2006
ACCESSION NUMBER: 2006:1327109 CAPLUS Full-text
DOCUMENT NUMBER: 146:243229
TITLE: SAR of a Series of 5,6-Dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridines as Potent Inhibitors of Human Eosinophil Phosphodiesterase
AUTHOR(S): Duplantier, Allen J.; Bachert, Elizabeth L.; Cheng, John B.; Cohan, Victoria L.; Jenkinson, Teresa H.; Kraus, Kenneth G.; McKechney, Michael W.; Pillar, Joann D.; Watson, John W.
CORPORATE SOURCE: Pfizer Global Research and Development, Groton, CT, 06340, USA
SOURCE: Journal of Medicinal Chemistry (2007), 50(2), 344-349
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 20 Dec 2006
GI



I

AB The potency and phys. properties of a previously reported 7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine series of human eosinophil phosphodiesterase inhibitors were improved by tying the lactam moiety into a triazolo ring. The resulting 5,6-dihydro-(9H)-pyrazolo[3,4- c]-1,2,4-triazolo[4,3-α]pyridine series provided nonionizable analogs with m.p. properties suitable for micronization. Substitution at the 3-position of the 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3- α]pyridine tricycle led to a 2-thienyl analog, 19 (tofimilast)(I), a potent PDE4 inhibitor with low oral bioavailability and no emesis-associated behaviors in ferrets at plasma concns. up to 152 ng/mL.

CC 1-3 (Pharmacology)
Section cross-reference(s): 27, 28

IT **185954-09-0P 185954-10-3P 185954-11-4P**
185954-12-5P 185954-14-7P 185954-15-8P
185954-17-0P 185954-19-2P 185954-23-8P
185954-26-1P 185954-27-2P, Tofimilast
185954-28-3P 185954-29-4P 185954-30-7P
185954-31-8P 185954-33-0P 185954-36-3P
185954-40-9P 185954-42-1P 477529-72-9P
925674-29-9P 925674-31-3P 925674-33-5P
925674-35-7P 925674-41-5P 925674-42-6P
925674-44-8P 925674-45-9P 925674-46-0P
925674-47-1P 925674-48-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(SAR of a Series of 5,6-Dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridines as Potent Inhibitors of Human Eosinophil Phosphodiesterase)

IT **185954-09-0P 185954-10-3P 185954-11-4P**
185954-12-5P 185954-14-7P 185954-15-8P
185954-17-0P 185954-19-2P 185954-23-8P
185954-26-1P 185954-27-2P, Tofimilast
185954-28-3P 185954-29-4P 185954-30-7P
185954-31-8P 185954-33-0P 185954-36-3P
185954-40-9P 185954-42-1P 477529-72-9P
925674-29-9P 925674-31-3P 925674-33-5P
925674-35-7P 925674-41-5P 925674-42-6P
925674-44-8P 925674-45-9P 925674-46-0P
925674-47-1P 925674-48-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(SAR of a Series of 5,6-Dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridines as Potent Inhibitors of Human Eosinophil Phosphodiesterase)

RN 185954-09-0 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(3-pyridinyl)- (CA INDEX NAME)



RN 185954-10-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-phenyl- (CA INDEX NAME)



RN 185954-11-4 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-3-(2-furanyl)-6,9-dihydro- (CA INDEX NAME)



RN 185954-12-5 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(3-methoxyphenyl)- (CA INDEX NAME)



RN 185954-14-7 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-methylphenyl)- (CA INDEX NAME)



RN 185954-15-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)



RN 185954-17-0 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-(3-chloro-4-methyl-2-thienyl)-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-19-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 185954-23-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-pyridinyl)- (CA INDEX NAME)



RN 185954-26-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-

6,9-dihydro-3-(4-pyridinyl)- (CA INDEX NAME)



RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-28-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-propyl- (CA INDEX NAME)



RN 185954-29-4 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-methyl- (CA INDEX NAME)



RN 185954-30-7 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-31-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-(3-chlorophenyl)-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-33-0 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3,9-dicyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-36-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(1-methylcyclohexyl)- (CA INDEX NAME)



RN 185954-40-9 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 477529-72-9 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(3-thienyl)- (CA INDEX NAME)



RN 925674-29-9 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(4-methoxyphenyl)- (CA INDEX NAME)



RN 925674-31-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(4-methylphenyl)- (CA INDEX NAME)



RN 925674-33-5 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-(4-chlorophenyl)-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 925674-35-7 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 925674-41-5 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3,7-diethyl-6,9-dihydro- (CA INDEX NAME)



RN 925674-42-6 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-butyl-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 925674-44-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-cyclobutyl-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 925674-45-9 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-cyclohexyl-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 925674-46-0 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 925674-47-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-3-(1-ethylpropyl)-6,9-dihydro- (CA INDEX NAME)



RN 925674-48-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-bicyclo[2.2.2]oct-1-yl-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 01 Dec 2006
ACCESSION NUMBER: 2006:1256669 CAPLUS Full-text
DOCUMENT NUMBER: 146:20293
TITLE: Novel medicament combinations for the treatment of respiratory diseases
INVENTOR(S): Pieper, Michael P.; Schnapp, Andreas; Nickolaus, Peter
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: U.S. Pat. Appl. Publ., 33pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006270667	A1	20061130	US 2006-420872	20060530
WO 2006128847	A2	20061207	WO 2006-EP62683	20060529
WO 2006128847	A3	20070426		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2005-104702 A 20050531

OTHER SOURCE(S): MARPAT 146:20293
ED Entered STN: 01 Dec 2006
AB The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, betamimetic, at least one anticholinergic and at least one PDE-IV inhibitor processes for preparing them and their use as pharmaceutical compns.
INCL 514230500; 514521000; 514651000; 514394000; 514312000; 514367000; 514305000; 514649000; 514643000; 514291000
CC 1-9 (Pharmacology)
Section cross-reference(s): 63
IT 58-55-9, Theophyllin 530-08-5, Isoetharine 596-51-0D, salts 7683-59-2, Isoprenaline 13642-52-9, Soterenol 18559-94-9, Albuterol 18910-65-1, Salmefamol 23031-25-6, Terbutaline 26652-09-5, Ritodrine 30392-40-6, Bitolterol 32527-55-2, Tiaramide 34391-04-3, Levosalbutamol 34866-47-2, Carbuterol 37148-27-9, Clenbuterol 41078-02-8, Enprofylline 42461-79-0, Sulfonterol 47608-32-2D, Trospium, salts 53034-85-8, Ibuterol 54063-54-6, Reproterol 56341-08-3 58020-43-2, HOKU-81 60205-81-4D, Ipratropium, salts 63516-07-4, Flutropium bromide 72332-33-3, Procaterol 73865-18-6 76596-57-1, Broxaterol 81732-65-2, Bambuterol 89365-50-4, Salmeterol 99571-64-9D, Oxitropium, salts 105738-28-1 125692-87-7, Tolubuterol 134865-33-1, Meluadrine 135637-46-6, Atizoram 136145-07-8, Arofylline 145739-56-6, Tetomilast 146426-61-1 147568-66-9, Carmoterol 153259-65-5 153587-17-8 154284-39-6 155043-84-8, T 440 162278-09-3, V-11294A 162401-32-3, Roflumilast 162542-90-7, CDP840 179024-48-7, PD 168787 **185954-27-2 185954-42-1** 186461-26-7, T 2585 186691-13-4D, Tiotropium, salts 190377-71-0, NCS 613 257892-33-4, AWD-12-281 257892-34-5, D-4418 292135-78-5 329306-27-6, Bay 19-8004 344466-42-8 345926-90-1 371754-04-0 371754-06-2 371754-07-3 371754-09-5 444659-35-2, YM 58997 444659-43-2, D-4396 452340-93-1 478409-36-8, CP 325366 832733-47-8, KUL 1248 835882-98-9 835882-99-0 836652-83-6, Z 15370 870265-42-2, TD 3327 916057-18-6 916057-19-7 916057-20-0 916057-21-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel medicament combinations for treatment of respiratory diseases)
IT **185954-27-2 185954-42-1**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel medicament combinations for treatment of respiratory diseases)
RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



L4 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 21 Jul 2006
ACCESSION NUMBER: 2006:708087 CAPLUS Full-text
DOCUMENT NUMBER: 145:152732
TITLE: Therapeutic agent for allergic conjunctival disease
INVENTOR(S): Shii, Daisuke; Miyake, Hideki
PATENT ASSIGNEE(S): Santen Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006075748	A1	20060720	WO 2006-JP300464	20060117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
JP 2006219487	A	20060824	JP 2006-8099	20060117
PRIORITY APPLN. INFO.:			JP 2005-8901 A	20050117

ED Entered STN: 21 Jul 2006
AB Disclosed is a novel pharmacol. efficacy of 9-cyclopentyl-7-ethyl-3-(thiophen-2-yl)-5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3- a]pyridine (tofimilast) and 2-(3-chlorophenoxy)-3-[3-(3-hydroxypyridin-4-yl)propoxy]pyridine. These substituted pyridine derivs. exhibit excellent allergic conjunctival symptom suppressing effects on allergic conjunctival models, so that they are useful as a therapeutic agent for allergic conjunctival diseases, such as allergic conjunctivitis, spring catarrh and atopic keratoconjunctivitis. For example, an eye drop solution contained tofimilast 100, concentrated glycerin 500, Polysorbate-80 1000 mg, NaH2PO4·2H2O q.s., NaOH (1N) q.s., HCl q.s., and distilled water to 100 mL.
CC 63-6 (Pharmaceuticals)
IT **185954-27-2**, Tofimilast 263391-17-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted pyridine derivs. as therapeutic agents for allergic conjunctival disease)
IT **185954-27-2**, Tofimilast

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted pyridine derivs. as therapeutic agents for allergic conjunctival disease)

RN 185954-27-2 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 17 Feb 2006
ACCESSION NUMBER: 2006:149262 CAPLUS Full-text
DOCUMENT NUMBER: 144:239931
TITLE: Pharmaceutical compositions for the treatment of respiratory and gastrointestinal disorders
INVENTOR(S): Jung, Birgit; Himmelsbach, Frank
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG
SOURCE: PCT Int. Appl., 321 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006015775	A2	20060216	WO 2005-EP8385	20050803
WO 2006015775	A3	20070518		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 2006035893	A1	20060216	US 2005-189643	20050726
CA 2575541	A1	20060216	CA 2005-2575541	20050803
EP 1784224	A2	20070516	EP 2005-773706	20050803
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRIORITY APPLN. INFO.: EP 2004-18808 A 20040807
WO 2005-EP8385 W 20050803

OTHER SOURCE(S): MARPAT 144:239931
ED Entered STN: 17 Feb 2006
AB The present invention relates to novel pharmaceutical compns. comprising at least 1 EGFR kinase inhibitor and at least one addnl. active compound selected from β-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists and endothelin-antagonists, processes for preparing the compns. and the use thereof as drugs in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes. Thus, an inhalable powder contained an EGFR kinase inhibitor 150, formoterol fumarate dihydrate 50, and lactose 12,300 mg/capsule.
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT 50-02-2 53-03-2, Prednisone 56-81-5, Glycerol, biological studies 57-55-6, Propylene glycol, biological studies 58-55-9, Theophylline, biological studies 64-17-5, Ethanol, biological studies 67-63-0, Isopropyl alcohol, biological studies 83-43-2, Methyl prednisolone 124-94-7, Triamcinolone 530-08-5, Isoetharine 586-06-1, Metaproterenol 3215-70-1, Hexoprenaline 3385-03-3, Flunisolide 4419-39-0 7683-59-2, Isoprenaline 13392-18-2, Fenoterol 13642-52-9, Soterenol 18559-94-9, Albuterol 18910-65-1, Salmefamol 23031-25-6, Terbutaline 25322-68-3, Polyethylene glycol 25322-68-3D, Polyethylene glycol, esters with fatty acids 25322-69-4, Polypropylene glycol 26652-09-5, Ritodrine 30392-40-6, Bitolterol 32527-55-2, Tiaramide 32953-89-2, Rimiterol 34391-04-3, Levosalbutamol 34866-47-2, Carbuterol 37148-27-9, Clenbuterol 38677-81-5, Pirbuterol 41078-02-8, Enprofylline 42461-79-0, Sulfonterol 51333-22-3, Budesonide 53034-85-8, Ibuterol 54063-54-6, Reproterol 56341-08-3, Mabuterol 58020-43-2 72332-33-3, Procaterol 73573-87-2, Formoterol 73865-18-6 76596-57-1, Broxaterol 80474-14-2, Fluticasone propionate 81732-65-2, Bambuterol 89365-50-4, Salmeterol 90566-53-3, Fluticasone 94749-08-3, Salmeterol xinafoate 94749-10-7 98449-05-9 105102-22-5, Mometasone 105738-28-1 125692-87-7, Tolubuterol 126544-47-6, Ciclesonide 134865-33-1, Meluadrine 135637-46-6 136145-07-8, Arofylline 137888-11-0 138449-07-7 138531-51-8 142001-63-6 144459-70-1, Rofleponide 145742-28-5 146426-61-1 146426-68-8 147116-64-1, CJ 11974 147536-97-8, Bosentan 153050-21-6, Nolpitantium chloride 153259-65-5, Ariflo 153587-17-8 154189-40-9 154284-39-6 155043-84-8 155418-05-6 155418-06-7, Nolpitantium besilate 159001-35-1 162117-90-0 162278-09-3 162401-32-3, Roflumilast 162412-70-6 162542-90-7 167256-08-8, Enrasentan 168266-90-8, GR 205171 170566-84-4 170729-80-3 171272-39-2 171714-88-8, PD 156123 172548-79-7 172673-20-0 173941-19-0, YM 49244 173941-22-5, YM 35375 173941-74-7, YM 44778 174636-32-9 174661-97-3 176960-47-7 178370-50-8, MDL 103896 179024-48-7, PD 168787 180288-69-1, Trastuzumab 180384-57-0, Tezosentan 180577-26-8, K 8794 182282-60-6 183321-74-6 183747-35-5 183814-30-4, Formoterol fumarate dihydrate 184036-34-8, Sitaxsentan **185954-27-2 185954-42-1** 186461-26-7, T 2585 186497-38-1, ZD-1611 187724-61-4 188241-50-1 188307-16-6, T 0201 190377-71-0, NCS 613 192056-77-2 192819-27-5 193694-35-8 201152-86-5 205923-56-4, Cetuximab 206052-25-7 207993-12-2, BY 343 209474-01-1 214487-46-4 217185-75-6 221246-12-4, PD 180988 231277-92-2 257892-33-4, AWD 12-281 257892-34-5 267243-28-7 285983-48-4 292135-78-5 294848-51-4 294848-58-1 294849-20-0 294849-36-8 294849-84-6 294850-04-7 294850-87-6 294851-64-2 294851-66-4 294851-76-6 312753-33-6 314771-10-3 314771-31-8 326894-84-2 329306-27-6 339177-26-3 345926-90-1 350610-25-2, BIIF 1149 350610-26-3, 6b-I 350610-27-4,

DNK 33A 350610-29-6, ZM 274773 350610-34-3, DNK 333A 350610-51-4, CGP 60829 350610-61-6, NKP 608A 350610-64-9, NKP 608C 371754-04-0
371754-06-2 371754-07-3 371754-09-5 371754-11-9 397864-44-7
402569-98-6 402573-59-5 402734-20-7 402735-03-9 402735-06-2
402735-09-5 402855-53-2 402855-58-7 402855-69-0 438245-34-2
439081-10-4 439081-11-5 439081-12-6 439081-13-7 439081-14-8
439081-17-1 439081-18-2 439081-24-0 439081-25-1 439081-26-2
439081-30-8 439081-39-7 439081-40-0 439081-48-8 444659-35-2, YM 58997 444659-43-2 452340-93-1 478409-36-8, CP 325366 573649-57-7
573649-59-9 581772-03-4 581772-04-5 581772-05-6 581772-06-7
581772-07-8 581772-08-9 581772-09-0 581772-10-3 581772-11-4
581772-12-5 581772-14-7 581772-15-8 581772-16-9 581772-17-0
581772-18-1 581772-19-2 582332-41-0 582332-76-1 609767-39-7
609767-43-3 609767-44-4 609767-45-5 609767-47-7 609767-50-2
609767-51-3 609767-54-6 609767-56-8 609767-57-9 609767-58-0
610302-28-8 610302-29-9 610302-30-2 610302-31-3 610302-33-5
610302-34-6 610302-39-1 610302-54-0 610302-58-4 610302-60-8
610302-62-0 610302-66-4 610302-68-6 610302-72-2 610302-76-6
610302-82-4 610302-83-5 610302-84-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. for treatment of respiratory and gastrointestinal disorders)

IT **185954-27-2 185954-42-1**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. for treatment of respiratory and gastrointestinal disorders)

RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



L4 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 18 Jan 2006
ACCESSION NUMBER: 2006:46803 CAPLUS Full-text
DOCUMENT NUMBER: 144:135233

TITLE: Pharmaceuticals for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Gm.b.H. & Co. K.-G., Germany
SOURCE: Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1616567	A1	20060118	EP 2004-16878	20040716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CA 2570433	A1	20060126	CA 2005-2570433	20050613
WO 2006008213	A1	20060126	WO 2005-EP52704	20050613
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:		
EP 2004-16878	A	20040716
WO 2005-EP52704	W	20050613

ED Entered STN: 18 Jan 2006

AB The present invention relates to novel pharmaceutical compns. based on PDE IV inhibitors and salts of glycopyrrolate salts, processes for preparing them and their use in the treatment of respiratory complaints. Thus, a formulation contained a glycopyrrolate salt 60, AWD 12281 200, lactose 12240 μg/capsule.

CC 63-6 (Pharmaceuticals)

IT 56-81-5, Glycerol, biological studies 57-55-6, 1,2-Propanediol, biological studies 58-55-9, Theophylline, biological studies 60-00-4, biological studies 64-02-8, Sodium Edetate 64-17-5, Ethanol, biological studies 67-63-0, 2-Propanol, biological studies 596-51-0 25322-68-3 25322-68-3D, Polyethylene glycol, esters with fatty acids 25322-69-4 41078-02-8 135637-46-6 136145-07-8, Arofylline 146426-61-1 153259-65-5, Cilomilast 153587-17-8 154284-39-6 155043-84-8 161918-68-9 162278-09-3 162401-32-3, Roflumilast 162542-90-7 179024-48-7, PD 168787 182282-60-6 **185954-27-2** **185954-42-1** 186461-26-7, T 2585 190377-71-0, NCS 613 192819-27-5 201932-04-9D, salts 202185-74-8D, salts 207993-12-2, BY 343 257892-34-5 292135-78-5 329306-27-6 444659-35-2, YM 58997 444659-43-2 475468-09-8 478409-36-8, CP 325366 586388-32-1 746600-85-1D, salts 754152-54-0D, salts 835882-98-9 835882-99-0 836652-75-6, C 1-1018 836652-82-5, CDC 3052 836652-83-6, Z 15370 873295-30-8 873295-31-9 873295-32-0 873295-33-1 873295-34-2 873295-35-3 873295-36-4 873295-37-5 873295-38-6 873295-39-7 873295-40-0 873295-41-1 873295-43-3 873295-44-4 873295-45-5 873295-46-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals for inhalation comprising PDE IV inhibitors and glycopyrrolate salts)

IT 185954-27-2 185954-42-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals for inhalation comprising PDE IV inhibitors and glycopyrrolate salts)
RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 09 Dec 2005
ACCESSION NUMBER: 2005:1289733 CAPLUS Full-text
DOCUMENT NUMBER: 144:40794
TITLE: Combinations comprising antimuscarinic agents and PDE4 inhibitors
INVENTOR(S): Gras Escardo, Jordi; Llenas Calvo, Jesus; Ryder, Hamish; Orviz Diaz, Pio
PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115465	A1	20051208	WO 2005-EP5839	20050531

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,

SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

ES	2257152	A1	20060716	ES 2004-1312	20040531
AU	2005247103	A1	20051208	AU 2005-247103	20050531
AU	2005247106	A1	20051208	AU 2005-247106	20050531
AU	2005247107	A1	20051208	AU 2005-247107	20050531
AU	2005247108	A1	20051208	AU 2005-247108	20050531
CA	2533061	A1	20051208	CA 2005-2533061	20050531
CA	2568566	A1	20051208	CA 2005-2568566	20050531
CA	2569074	A1	20051208	CA 2005-2569074	20050531
CA	2569077	A1	20051208	CA 2005-2569077	20050531
LU	91214	A1	20060126	LU 2005-91214	20050531
GB	2419819	A	20060510	GB 2005-26502	20050531
GB	2419819	B	20070221		
JP	2006527183	T	20061130	JP 2006-508319	20050531
EP	1761279	A1	20070314	EP 2005-746222	20050531

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

EP	1761280	A1	20070314	EP 2005-747758	20050531

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

EP	1763368	A1	20070321	EP 2005-750538	20050531

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

EP	1763369	A1	20070321	EP 2005-751702	20050531

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

CN	1960759	A	20070509	CN 2005-80017685	20050531
CN	1960761	A	20070509	CN 2005-80017693	20050531
CN	1960762	A	20070509	CN 2005-80017695	20050531
CN	1972716	A	20070530	CN 2005-80017694	20050531
US	2006154934	A1	20060713	US 2006-375308	20060314
US	2006205702	A1	20060914	US 2006-405888	20060418
HK	1090306	A1	20070504	HK 2006-112215	20061107
NO	2006005477	A	20061222	NO 2006-5477	20061128
NO	2006005482	A	20061222	NO 2006-5482	20061128
NO	2006005483	A	20061222	NO 2006-5483	20061128
NO	2006005478	A	20061228	NO 2006-5478	20061128
IN	2006DN07293	A	20070427	IN 2006-DN7293	20061204

PRIORITY APPLN. INFO.:	ES 2004-1312	A	20040531
	WO 2005-EP1969	A	20050224
	WO 2005-GB722	A	20050225
	WO 2005-GB740	A	20050225
	US 2005-141169	B1	20050531
	US 2005-141427	B1	20050531
	WO 2005-EP5836	W	20050531
	WO 2005-EP5839	W	20050531
	WO 2005-EP5840	W	20050531
	WO 2005-EP5841	W	20050531

ED. Entered STN: 09 Dec 2005

AB A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9- carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.

IC ICM A61K045-00
ICS A61K031-439; A61K031-167; A61K031-137; A61P011-00; A61P011-06; A61P011-08

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 2

IT 58-55-9, Theophylline, biological studies 985-12-6, Drotaverine hydrochloride 41078-02-8, Enprofylline 57076-71-8, Denbufylline 61413-54-5, Rolipram 87714-57-6, MN 001 (surfactant) 132210-43-6, Cipamfylline 136145-07-8, Arofylline 141184-34-1, Filaminast 144035-83-6, Piclamilast 145739-56-6, Tetomilast 153259-65-5, Cilomilast 162401-32-3, Roflumilast 162542-90-7 **185954-27-2**, Tofimilast 189940-24-7, Mesopram 192819-27-5, CDC-801 257892-33-4 320347-44-2 329306-27-6, Lirimilast 467421-06-3, CC 1088 608141-41-9, CC 10004 870772-71-7, ONO 6126
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations comprising antimuscarinic agents and PDE4 inhibitors)

IT **185954-27-2**, Tofimilast
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations comprising antimuscarinic agents and PDE4 inhibitors)

RN 185954-27-2 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 28 Oct 2005
ACCESSION NUMBER: 2005:1155523 CAPLUS Full-text
DOCUMENT NUMBER: 143:416252
TITLE: Novel medicament combinations for the treatment of respiratory diseases
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: U.S. Pat. Appl. Publ., 50 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005239778	A1	20051027	US 2005-109094	20050419

DE 102004019540 A1 20051110 DE 2004-102004019540 20040422
DE 102004052987 A1 20060504 DE 2004-102004052987 20041103
AU 2005235419 A1 20051103 AU 2005-235419 20050418
CA 2559699 A1 20051103 CA 2005-2559699 20050418
WO 2005102349 A1 20051103 WO 2005-EP4073 20050418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1781298 A1 20070509 EP 2005-739576 20050418
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
NO 2006005060 A 20061121 NO 2006-5060 20061102
PRIORITY APPLN. INFO.: DE 2004-102004019540A 20040422
US 2004-578542P P 20040610
DE 2004-102004052987A 20041103
EP 2005-2496 A 20050207
WO 2005-EP4073 W 20050418
OTHER SOURCE(S): MARPAT 143:416252
ED Entered STN: 28 Oct 2005
GI



I

AB The present invention relates to a pharmaceutical composition comprising one or more compds. of formula I wherein n denotes 1 or 2; R1 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl; R2 denotes hydrogen, halogen, C1-C4-alkyl or -O-C1-C4-alkyl; R3 denotes C1-C4-alkyl, OH, halogen, -O-C1-C4-alkyl, -O-C1-C4-alkylene-COOH, -O-C1-C4-alkylene-CO-O-C1-C4- alkyl, and at least one other active substance for the treatment of respiratory diseases. The second active substance can by an anticholinergic, a phosphodiesterase IV inhibitor, a steroid, a LTD4 antagonist or an EGFR inhibitor.

IC ICM A61K031-538
ICS A61K031-56
INCL 514230500; 514171000
CC 1-9 (Pharmacology)
Section cross-reference(s): 2, 28, 63
IT 58-55-9, Theophylline, biological studies 41078-02-8, Enprofylline 135637-46-6, Atizoram 136145-07-8, Arofylline 146426-61-1 146426-68-8 153259-65-5, Ariflo 153587-17-8 154284-39-6 155043-84-8, T-440 162278-09-3, V-11294A 162401-32-3, Roflumilast 162542-90-7, CDP840 179024-48-7, PD 168787 182282-60-6, D-22888

185954-27-2 185954-42-1 186461-26-7, T 2585
190377-71-0, NCS 613 192819-27-5, CDC-801 207993-12-2, Pumafentrine
257892-33-4, AWD-12-281 257892-34-5, D-4418 292135-78-5 329306-27-6
444659-35-2, YM 58997 444659-43-2, Sch-351591 478409-36-8, CP 325366
835882-98-9 835882-99-0 836652-75-6, C 1-1018 836652-82-5, CDC 3052
836652-83-6, Z 15370
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase IV inhibitor; novel medicament combinations for treatment of respiratory diseases)

IT **185954-27-2 185954-42-1**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase IV inhibitor; novel medicament combinations for treatment of respiratory diseases)

RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



L4 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 15 Jul 2005
ACCESSION NUMBER: 2005:614587 CAPLUS Full-text
DOCUMENT NUMBER: 143:139176
TITLE: Pharmaceutical compositions based on a scopine ester and nicotinamide derivatives
INVENTOR(S): Meade, Christopher J. Montague; Pairet, Michel; Pieper, Michael P.
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany
SOURCE: U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005154006	A1	20050714	US 2004-5122	20041206
CA 2547394	A1	20050728	CA 2005-2547394	20050104
WO 2005067929	A1	20050728	WO 2005-EP10	20050104

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1706118	A1	20061004	EP 2005-700675	20050104

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

PRIORITY APPLN. INFO.: EP 2004-327 A 20040109
US 2004-556807P P 20040326
WO 2005-EP10 W 20050104

OTHER SOURCE(S): MARPAT 143:139176
ED Entered STN: 15 Jul 2005
GI



I

AB The present invention relates to novel pharmaceutical compns. based on a scopine ester of formula (I), wherein X- has the meanings specified in the description and claims and one more, preferably one nicotinamide derivative, processes for preparing them and their use in the treatment of respiratory diseases.

IC ICM A61K031-4745
INCL 514291000
CC 63-6 (Pharmaceuticals)
IT 498-45-3D, Scopine, esters 179024-48-7 **185954-27-2**
185954-42-1 197894-77-2 197894-84-1 260361-27-1
321527-81-5 321527-82-6 321527-83-7 445295-04-5 445492-58-0
445492-59-1 445492-60-4 445492-61-5 445492-73-9 445492-74-0
445492-75-1 445492-76-2 445492-77-3 445492-78-4 445492-79-5
445492-80-8 445492-81-9 445492-82-0 445492-83-1 445492-84-2
445492-85-3 445492-86-4 445492-87-5 445492-88-6 445492-89-7
445492-90-0 445492-91-1 445492-92-2 445492-93-3 445492-94-4
445492-95-5 445492-96-6 445492-97-7 445492-98-8 445492-99-9

445493-00-5 445493-01-6 581772-03-4 581772-04-5 581772-05-6
581772-06-7 581772-07-8 581772-08-9 581772-09-0 581772-10-3
581772-11-4 581772-12-5 581772-13-6 581772-14-7 581772-15-8
581772-16-9 581772-17-0 581772-18-1 581772-19-2 581772-22-7
857900-47-1 857900-48-2 857900-49-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. based on a scopine ester and nicotinamide derivs.)

IT **185954-27-2 185954-42-1**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. based on a scopine ester and nicotinamide derivs.)

RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



L4 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 17 Feb 2005
ACCESSION NUMBER: 2005:136543 CAPLUS Full-text
DOCUMENT NUMBER: 142:246142
TITLE: Medicaments comprising PDE IV inhibitors and an anticholinergic agent for treating respiratory disorders
INVENTOR(S): Germeyer, Sabine; Meade, Christopher John Montague; Meissner, Helmut; Morschhaeuser, Gerd; Pairet, Michel; Pestel, Sabine; Pieper, Michael P.; Pohl, Gerald; Reichl, Richard; Speck, Georg
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013967	A1	20050217	WO 2004-EP8003	20040723
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005043343	A1	20050224	US 2004-891562	20040715
CA 2533786	A1	20050217	CA 2004-2533786	20040723
EP 1651208	A1	20060503	EP 2004-741118	20040723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007500148	T	20070111	JP 2006-521453	20040723
PRIORITY APPLN. INFO.:			EP 2003-17039	A 20030728
			US 2003-508119P	P 20031002
			WO 2004-EP8003	W 20040723

OTHER SOURCE(S): MARPAT 142:246142

ED Entered STN: 17 Feb 2005

AB The present invention relates to pharmaceutical compns. based on PDE IV inhibitors and salts of a novel anticholinergic, processes for preparing them and their use in the treatment of respiratory complaints. For example, scopine 9-methylfluorene-9-carboxylate methobromide was prepared and formulated into inhalable powder containing the drug 80 μg, AWD-12-281 200 μg, and lactose 12220 μg per capsule.

IC ICM A61K031-335
ICS A61K031-192; A61K031-44; A61P011-00; A61K045-06; A61K031-46

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 28

IT 56-81-5, Glycerol, biological studies 57-55-6, Propylene glycol, biological studies 58-55-9, Theophylline, biological studies 60-00-4, Edetic acid, biological studies 63-42-3, Lactose 64-02-8, Sodium edetate 64-17-5, Ethanol, biological studies 67-63-0, Isopropyl alcohol, biological studies 25322-68-3, Polyethylene glycol 25322-69-4, Polypropylene glycol 41078-02-8, Enprofylline 135637-46-6, Atizoram 136145-07-8, Arofylline 146426-61-1 153259-65-5 153587-17-8 154284-39-6 155043-84-8, T-440 162278-09-3, V-11294A 162401-32-3, Roflumilast 162542-90-7, CDP840 179024-48-7, PD 168787 182282-60-6, D-22888 **185954-27-2 185954-42-1** 186461-26-7, T 2585 190377-71-0, NCS 613 192819-27-5, CDC-801 257892-34-5, D-4418 292135-78-5 329306-27-6 444659-35-2, YM 58997 478409-36-8, CP 325366 581772-04-5 581772-05-6 581772-06-7 581772-07-8 581772-08-9 581772-09-0 581772-10-3 581772-11-4 581772-12-5 581772-13-6 581772-14-7 581772-15-8 581772-16-9 581772-17-0 581772-18-1 581772-19-2 582332-31-8 582332-41-0 735261-98-0D, salts 835882-98-9 835882-99-0 836652-75-6, C 1-1018 836652-82-5, CDC 3052 836652-83-6, Z 15370
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalable compns. comprising anticholinergic agent and PDE IV inhibitors for treating respiratory disorders)

IT **185954-27-2 185954-42-1**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhalable compns. comprising anticholinergic agent and PDE IV inhibitors for treating respiratory disorders)

RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 04 Feb 2005
ACCESSION NUMBER: 2005:99152 CAPLUS Full-text
DOCUMENT NUMBER: 142:204737
TITLE: Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
INVENTOR(S): Meade, Christopher John Montague; Pairet, Michel; Pieper, Michel; Pieper, Michael P.
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany
SOURCE: U.S. Pat. Appl. Publ., 18 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005026886	A1	20050203	US 2004-891551	20040715
CA 2534125	A1	20050217	CA 2004-2534125	20040717
WO 2005013993	A1	20050217	WO 2004-EP8024	20040717

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1651222	A1	20060503	EP 2004-741128	20040717
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007500149	T	20070111	JP 2006-521459	20040717
PRIORITY APPLN. INFO.:			EP 2003-17164	A 20030729
			US 2003-508125P	P 20031002
			WO 2004-EP8024	W 20040717

OTHER SOURCE(S): MARPAT 142:204737
ED Entered STN: 04 Feb 2005
GI



I

AB A pharmaceutical composition comprises: (a) a compound of formula I wherein X- is an anion with a single neg. charge; and (b) a PDE IV inhibitor, or an enantiomer, mixture of enantiomers, racemate, solvate, or hydrate thereof. A processes for preparing them, and their use in the treatment of respiratory complaints is also disclosed. A suspension aerosol contained I bromide 0.050, AWD-12-281 0.060, soya lecithin 0.2 and TG 134a:TG 227 (2:3) q.s. 100%.

IC ICM A61K031-56
ICS A61K031-522; A61K031-4745; A61K031-44
INCL 514171000; 514305000; 514345000; 514263320
CC 63-6 (Pharmaceuticals)
IT 58-55-9, Theophylline, biological studies 41078-02-8, Enprofylline 135637-46-6, Atizoram 136145-07-8, Arofylline 146426-61-1 153259-65-5 153587-17-8 154284-39-6 155043-84-8, T 440 162278-09-3, V-11294A 162401-32-3, Roflumilast 162542-90-7, CDP840 179024-48-7, PD 168787 182282-60-6, D-22888 **185954-27-2** **185954-42-1** 186461-26-7, T 2585 190377-71-0, NCS 613 192819-27-5, CDC-801 207993-12-2, BY 343 257892-33-4, AWD-12-281 257892-34-5, D-4418 292135-78-5 329306-27-6, Bay 19-8004 444659-35-2, YM 58997 444659-43-2, D 4396 478409-36-8, CP 325366 581772-04-5 581772-05-6 581772-06-7 581772-07-8 581772-08-9 581772-09-0 581772-10-3 581772-11-4 581772-12-5 581772-13-6 581772-14-7 581772-16-9 581772-17-0 581772-18-1 581772-19-2 582332-31-8 582332-41-0 760163-21-1 835614-29-4 835882-98-9 835882-99-0 836652-75-6, C 1-1018 836652-82-5, CDC 3052 836652-83-6, Z 15370
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicaments for inhalation comprising anticholinergic and PDE IV

inhibitor)
IT 185954-27-2 185954-42-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicaments for inhalation comprising anticholinergic and PDE IV inhibitor)
RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



L4 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 16 Jan 2004
ACCESSION NUMBER: 2004:36706 CAPLUS Full-text
DOCUMENT NUMBER: 140:94049
TITLE: Preparation of pyrazolopyridinones as intermediates for synthesis of pyrazolotriazolopyridines
INVENTOR(S): Urban, Frank John
PATENT ASSIGNEE(S): Pfizer Products, Inc., USA
SOURCE: Eur. Pat. Appl., 39 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1380585	A1	20040114	EP 2003-24166	20000407
EP 1380585	B1	20041110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
EP 1048667	A1	20001102	EP 2000-302947	20000407
EP 1048667	B1	20031022		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: US 1999-131949P P 19990430
EP 2000-302947 A3 20000407

ED Entered STN: 16 Jan 2004
GI



I



II



III

AB The invention concerns the tosylate and besylate salts of the pyrazolopyridinone I. The compound I was prepared by reacting 3-methoxy-1-(4-methoxybenzyl)-4-propionyl-5,6-dihydro-1H-pyridin-2-one with cyclopentylhydrazine.2HCl (preparation of the reactants given). The compound I was then deprotected and converted into II which was subsequently reacted with 2-thiophenecarboxylic hydrazide to give the pyrazolotriazolopyridine III.

IC ICM C07D471-04
ICS C07D231-00; C07D221-00

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))

IT **185954-27-2P 185954-42-1P** 303752-13-8P 303752-15-0P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrazolopyridinones as intermediates for synthesis of pyrazolotriazolopyridines)

IT **185954-27-2P 185954-42-1P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrazolopyridinones as intermediates for synthesis of pyrazolotriazolopyridines)

RN 185954-27-2 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 26 Dec 2003
ACCESSION NUMBER: 2003:1006815 CAPLUS Full-text
DOCUMENT NUMBER: 140:35974
TITLE: Treatment for depression and anxiety by the combination of a PDE IV inhibitor and an antidepressant or an anxiolytic agent
INVENTOR(S): Sobolov-Jaynes, Susan Beth; Schmidt, Christopher Joseph
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003105902	A1	20031224	WO 2003-IB2295		20030605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2003235631	A1	20031225	US 2003-387060		20030312
CA 2488138	A1	20031224	CA 2003-2488138		20030605
AU 2003233032	A1	20031231	AU 2003-233032		20030605
EP 1517707	A1	20050330	EP 2003-727833		20030605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003011903	A	20050607	BR 2003-11903		20030605
JP 2005533788	T	20051110	JP 2004-512802		20030605
IN 2004CN03177	A	20060303	IN 2004-CN3177		20041213
PRIORITY APPLN. INFO.:			US 2002-389181P	P	20020617
			WO 2003-IB2295	W	20030605

OTHER SOURCE(S): MARPAT 140:35974
ED Entered STN: 26 Dec 2003
AB The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a PDE IV inhibitor in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compns. containing a pharmaceutically acceptable carrier, a PDE IV inhibitor and an anxiolytic agent or antidepressant.
IC ICM A61K045-06
ICS A61P025-22; A61P025-24
CC 1-11 (Pharmacology)
IT 50-48-6, Amitriptyline 50-49-7, Imipramine 51-71-8, Phenelzine 59-63-2, Isocarboxazid 155-09-9, Tranylcypromine 19794-93-5, Trazodone 24219-97-4, Mianserin 25905-77-5, Minaprine 34911-55-2, Bupropion 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 56775-88-3, Zimelidine 59729-33-8, Citalopram 61413-54-5 61869-08-7, Paroxetine 72797-41-2, Tianeptine 79617-96-2, Sertraline 83366-66-9, Nefazodone 85650-52-8, Mirtazapine 92623-85-3, Milnacipran 93413-69-5, Venlafaxine 116539-59-4, Duloxetine 121851-47-6 128196-01-0, Escitalopram 132210-43-6, Cipamfylline 153259-65-5, Cilomilast 161178-10-5, Lubazodone hydrochloride 162278-09-3, V-11294A 162401-32-3, Roflumilast 163521-12-8 180529-63-9 **185954-27-2**, Tofimilast 189940-24-7, Mesopram 190204-71-8 191219-80-4, YM-976 192767-01-4 192819-27-5, CDC-801 197894-84-1, CI-1044 203382-47-2 207279-23-0 207993-12-2, Pumafentrine 225100-00-5 256443-69-3 259744-67-7 260561-48-6 264123-38-8 266997-39-1 298680-25-8 299157-88-3 300781-85-5 305802-43-1 306759-92-2 308094-69-1 308285-76-9 308340-86-5 325770-75-0 329306-27-6, BAY 19-8004 337358-64-2 337359-69-0 337376-23-5 346408-85-3 346441-11-0 347191-74-6 347885-03-4 348078-16-0 348078-23-9 349494-81-1 353280-07-6 353458-31-8 358972-78-8 358976-71-3 359001-45-9 360042-76-8 362718-38-5 413614-82-1 426268-06-6 444659-43-2, SCH-351591 491869-01-3 636598-43-1 636598-44-2 636598-45-3 636598-46-4 636598-47-5 636598-48-6 636598-49-7 636598-50-0 636598-51-1 636598-52-2 636598-53-3 636598-54-4 636598-55-5 636598-56-6 636598-57-7 636598-58-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment for depression and anxiety by combination of a PDE IV inhibitor and an antidepressant or an anxiolytic agent)
IT **185954-27-2**, Tofimilast
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment for depression and anxiety by combination of a PDE IV inhibitor and an antidepressant or an anxiolytic agent)
RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 13 Jun 2003
ACCESSION NUMBER: 2003:454118 CAPLUS Full-text
DOCUMENT NUMBER: 139:17580
TITLE: Combination of a selective PDE4 inhibitor and an adrenergic β-2 receptor agonist in treatment of inflammatory diseases
INVENTOR(S): Yeadon, Michael
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003047578	A1	20030612	WO 2002-IB4922		20021122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2468676	A1	20030612	CA 2002-2468676		20021122
AU 2002353255	A1	20030617	AU 2002-353255		20021122
EP 1455783	A1	20040915	EP 2002-788275		20021122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002014776	A	20041109	BR 2002-14776		20021122
CN 1599609	A	20050323	CN 2002-824393		20021122
HU 200402546	A2	20050428	HU 2004-2546		20021122
JP 2005511657	T	20050428	JP 2003-548833		20021122
NZ 533030	A	20070330	NZ 2002-533030		20021122
US 2003119862	A1	20030626	US 2002-308962		20021203
TW 242433	B	20051101	TW 2002-91135479		20021206
US 2004167153	A1	20040826	US 2003-736996		20031216
ZA 2004003905	A	20050622	ZA 2004-3905		20040520
NO 2004002870	A	20040706	NO 2004-2870		20040706
IN 2004DN01375	A	20050401	IN 2004-DN1375		20041121
PRIORITY APPLN. INFO.:			GB 2001-29395	A	20011207
			US 2002-352388P	P	20020128
			WO 2002-IB4922	W	20021122

OTHER SOURCE(S): MARPAT 139:17580
ED Entered STN: 13 Jun 2003
GI



I

AB The present invention relates to a combination of a selective PDE4 inhibitor, as defined herein, and an adrenergic β-2 receptor agonist for simultaneous, sequential or sep. administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease. Combined application of β-2 agonists such as formoterol or salmeterol with a PDE-4 inhibitor such as I produces synergistic inhibition of proinflammatory neutrophil function.

IC ICM A61K031-44
ICS A61K045-06; A61P011-00

CC 1-9 (Pharmacology)
Section cross-reference(s): 63

IT 73573-87-2, Formoterol 89365-50-4, Salmeterol **185954-27-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of a selective PDE4 inhibitor and an adrenergic β-2 receptor agonist in treatment of inflammatory diseases)

IT **185954-10-3 185954-11-4 185954-14-7**
185954-15-8 185954-19-2 185954-23-8
185954-26-1 185954-28-3 185954-30-7
185954-33-0 185954-36-3 185954-39-6
185954-40-9 185954-42-1 185954-43-2
477529-72-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of a selective PDE4 inhibitor and an adrenergic β-2 receptor agonist in treatment of inflammatory diseases)

IT **185954-27-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of a selective PDE4 inhibitor and an adrenergic β-2 receptor agonist in treatment of inflammatory diseases)

RN 185954-27-2 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



IT **185954-10-3 185954-11-4 185954-14-7**
185954-15-8 185954-19-2 185954-23-8
185954-26-1 185954-28-3 185954-30-7
185954-33-0 185954-36-3 185954-39-6
185954-40-9 185954-42-1 477529-72-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of a selective PDE4 inhibitor and an adrenergic β-2 receptor agonist in treatment of inflammatory diseases)

RN 185954-10-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-phenyl- (CA INDEX NAME)



RN 185954-11-4 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-3-(2-furanyl)-6,9-dihydro- (CA INDEX NAME)



RN 185954-14-7 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-methylphenyl)- (CA INDEX NAME)



RN 185954-15-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)



RN 185954-19-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 185954-23-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-pyridinyl)- (CA INDEX NAME)



RN 185954-26-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(4-pyridinyl)- (CA INDEX NAME)



RN 185954-28-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-propyl- (CA INDEX NAME)



RN 185954-30-7 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-33-0 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3,9-dicyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-36-3 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(1-methylcyclohexyl)- (CA INDEX NAME)



RN 185954-39-6 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-iodophenyl)- (9CI) (CA INDEX NAME)



RN 185954-40-9 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 477529-72-9 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(3-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 21 Mar 2003
ACCESSION NUMBER: 2003:221514 CAPLUS Full-text
DOCUMENT NUMBER: 138:243317
TITLE: Inhalation compositions comprising tricyclic 5,6-dihydro-9H-pyrazolo(3,4-c)-1,2,4-triazolo[4,3-a]pyridines and a tiotropium salt
INVENTOR(S): Humphrey, Michael John; Miller, Paul Robert; Shepherd, Michael Trevor
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022279	A1	20030320	WO 2002-IB3598	20020902
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002334256	A1	20030324	AU 2002-334256	20020902
CN 1553801	A	20041208	CN 2002-817887	20020902
US 2003064034	A1	20030403	US 2002-236228	20020905
US 2003064031	A1	20030403	US 2002-236551	20020905
ZA 2004001002	A	20050207	ZA 2004-1002	20040206
BG 108569	A	20050228	BG 2004-108569	20040209
US 2005232871	A1	20051020	US 2005-152741	20050613
PRIORITY APPLN. INFO.:			GB 2001-22031	A 20010912
			US 2001-325709P	P 20010927
			WO 2002-IB3598	W 20020902
			US 2002-236228	A1 20020905

OTHER SOURCE(S): MARPAT 138:243317
ED Entered STN: 21 Mar 2003
GI



I

AB The present invention relates to an inhaled formulation comprising a combination of a compound selected from a particular class of 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridines and a tiotropium salt or solvate thereof, which is capable of delivering the compound as fine, solid particles to the lung. The invention also relates to the use of such a formulation in the treatment of certain diseases such as respiratory diseases. By the use of such formulations, it is possible to eliminate the unwanted cough response associated with the use of the compds. in solution metered dose inhalers, which response can prevent the administration of a therapeutically ED and, in the long term, undermine patient compliance. Dry powder inhaler capsules were prepared containing I and lactose monohydrate.

IC ICM A61K031-46
ICS A61K031-437; A61K009-14; A61K009-72; A61P011-00; A61P011-06; A61K031-46; A61K031-437
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT **185954-10-3 185954-11-4 185954-14-7 185954-15-8 185954-19-2 185954-23-8 185954-26-1 185954-27-2 185954-28-3 185954-30-7 185954-33-0 185954-36-3**

185954-39-6 185954-40-9 185954-42-1
185954-43-2 477529-72-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalation compns. comprising tricyclic 5,6-dihydro-9H-pyrazolo(3,4-c)-1,2,4-triazolo[4,3-a]pyridines and a tiotropium salt)

IT 185954-10-3 185954-11-4 185954-14-7
185954-15-8 185954-19-2 185954-23-8
185954-26-1 185954-27-2 185954-28-3
185954-30-7 185954-33-0 185954-36-3
185954-39-6 185954-40-9 185954-42-1
477529-72-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalation compns. comprising tricyclic 5,6-dihydro-9H-pyrazolo(3,4-c)-1,2,4-triazolo[4,3-a]pyridines and a tiotropium salt)

RN 185954-10-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-phenyl- (CA INDEX NAME)



RN 185954-11-4 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-3-(2-furanyl)-6,9-dihydro- (CA INDEX NAME)



RN 185954-14-7 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-methylphenyl)- (CA INDEX NAME)



RN 185954-15-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)



RN 185954-19-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 185954-23-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-pyridinyl)- (CA INDEX NAME)



RN 185954-26-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(4-pyridinyl)- (CA INDEX NAME)



RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-28-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-propyl- (CA INDEX NAME)



RN 185954-30-7 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-33-0 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3,9-dicyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-36-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(1-methylcyclohexyl)- (CA INDEX NAME)



RN 185954-39-6 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-iodophenyl)- (9CI) (CA INDEX NAME)



RN 185954-40-9 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 477529-72-9 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(3-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 21 Mar 2003
ACCESSION NUMBER: 2003:221511 CAPLUS Full-text
DOCUMENT NUMBER: 138:243315
TITLE: Inhalation compositions comprising tricyclic 5,6-dihydro-9H-pyrazolo(3,4-c)-1,2,4-triazolo[4,3-a]pyridines
INVENTOR(S): Humphrey, Michael John; Miller, Paul Robert; Shepherd, Michael Trevor
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022275	A1	20030320	WO 2002-IB3599	20020902
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2457717	A1	20030320	CA 2002-2457717	20020902
AU 2002330687	A1	20030324	AU 2002-330687	20020902
EE 200400078	A	20040615	EE 2004-78	20020902
EP 1427414	A1	20040616	EP 2002-767763	20020902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012449	A	20040817	BR 2002-12449	20020902
CN 1553801	A	20041208	CN 2002-817887	20020902
HU 200401890	A2	20041228	HU 2004-1890	20020902
JP 2005505560	T	20050224	JP 2003-526404	20020902
NZ 530929	A	20060831	NZ 2002-530929	20020902
US 2003064034	A1	20030403	US 2002-236228	20020905
US 2003064031	A1	20030403	US 2002-236551	20020905
ZA 2004001002	A	20050207	ZA 2004-1002	20040206
BG 108569	A	20050228	BG 2004-108569	20040209
NO 2004001011	A	20040310	NO 2004-1011	20040310
IN 2005MN00216	A	20050930	IN 2005-MN216	20050321

US 2005232871 A1 20051020 US 2005-152741 20050613
PRIORITY APPLN. INFO.: GB 2001-22031 A 20010912
US 2001-325709P P 20010927
WO 2002-IB3599 W 20020902
US 2002-236228 A1 20020905
IN 2004-MN110 A3 20040213

OTHER SOURCE(S): MARPAT 138:243315
ED Entered STN: 21 Mar 2003
GI



I

AB The present invention relates to an inhaled formulation comprising a compound selected from a particular class of 5,6-dihydro-9H-pyrazolo[3,4-c]- 1,2,4-triazolo[4,3-a]pyridines which is capable of delivering the compound as fine, solid particles to the lung and the use of such a formulation in the treatment of certain diseases such as respiratory diseases. By the use of such formulations, it is possible to eliminate the unwanted cough response associated with the use of these compds. in solution metered dose inhalers, which response can prevent the administration of a therapeutically ED and, in the long term, undermine patient compliance. A dry powder inhaler capsule was prepared containing micronized I and lactose monohydrate.

IC ICM A61K031-437
ICS A61K009-14; A61K009-72; A61P011-00; A61P011-06
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT **185954-27-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalation compns. comprising tricyclic 5,6-dihydro-9H-pyrazolo(3,4-c)-1,2,4-triazolo[4,3-a]pyridines)
IT **185954-10-3 185954-11-4 185954-14-7**
185954-15-8 185954-19-2 185954-23-8
185954-26-1 185954-28-3 185954-30-7
185954-33-0 185954-36-3 185954-39-6
185954-40-9 185954-42-1 185954-43-2
477529-72-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalation compns. comprising tricyclic 5,6-dihydro-9H-pyrazolo(3,4-c)-1,2,4-triazolo[4,3-a]pyridines)
IT **185954-27-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalation compns. comprising tricyclic 5,6-dihydro-9H-pyrazolo(3,4-c)-1,2,4-triazolo[4,3-a]pyridines)
RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



IT 185954-10-3 185954-11-4 185954-14-7
185954-15-8 185954-19-2 185954-23-8
185954-26-1 185954-28-3 185954-30-7
185954-33-0 185954-36-3 185954-39-6
185954-40-9 185954-42-1 477529-72-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalation compns. comprising tricyclic 5,6-dihydro-9H-pyrazolo(3,4-c)-1,2,4-triazolo[4,3-a]pyridines)

RN 185954-10-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-phenyl- (CA INDEX NAME)



RN 185954-11-4 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-3-(2-furanyl)-6,9-dihydro- (CA INDEX NAME)



RN 185954-14-7 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-methylphenyl)- (CA INDEX NAME)



RN 185954-15-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)



RN 185954-19-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 185954-23-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-pyridinyl)- (CA INDEX NAME)



RN 185954-26-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(4-pyridinyl)- (CA INDEX NAME)



RN 185954-28-3 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-propyl- (CA INDEX NAME)



RN 185954-30-7 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-33-0 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3,9-dicyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-36-3 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(1-methylcyclohexyl)- (CA INDEX NAME)



RN 185954-39-6 CAPLUS

CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-iodophenyl)- (9CI) (CA INDEX NAME)



RN 185954-40-9 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 477529-72-9 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(3-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 06 Dec 2002

ACCESSION NUMBER: 2002:927276 CAPLUS Full-text
DOCUMENT NUMBER: 138:11421
TITLE: A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
INVENTOR(S): Yeadon, Michael; Watson, John W.; Armstrong, Roisin A.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096463	A1	20021205	WO 2002-EP5726	20020524
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2446613	A1	20021205	CA 2002-2446613	20020524
AU 2002344167	A1	20021209	AU 2002-344167	20020524
EP 1395288	A1	20040310	EP 2002-750977	20020524
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002009992	A	20040406	BR 2002-9992	20020524
EE 200300585	A	20040415	EE 2003-585	20020524
HU 200400037	A2	20040428	HU 2004-37	20020524
CN 1511042	A	20040707	CN 2002-810498	20020524
JP 2005508861	T	20050407	JP 2002-592972	20020524
NZ 529335	A	20050930	NZ 2002-529335	20020524
ZA 2003008602	A	20050204	ZA 2003-8602	20031104
IN 2003MN01033	A	20051021	IN 2003-MN1033	20031111
US 2004147544	A1	20040729	US 2003-478755	20031121
BG 108382	A	20041230	BG 2003-108382	20031124
PRIORITY APPLN. INFO.:			US 2001-293606P P	20010525
			GB 2001-29396 A	20011207
			GB 2002-10240 A	20020503
			WO 2002-EP5726 W	20020524

OTHER SOURCE(S): MARPAT 138:11421
ED Entered STN: 06 Dec 2002
GI



I

AB The present invention discusses combination of a selective PDE4 inhibitor I [R1 = H, (C1-6) alkyl, alkoxy, Ph cycloalkyl etc.; R2, R3 = H, (C1-14) alkyl,

(C2-14)alkenyl, (C1-7)alkoxy etc.; R9, R10 = (C1-6) alkyl, alkoxy, (C6-10)aryl and aryloxy] and an anticholinergic agent for simultaneous, sequential or sep. administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease, with the proviso that the anticholinergic agent is not a tiotropium salt.

IC ICM A61K045-06
ICS A61P011-00; A61K031-46

CC 1-9 (Pharmacology)
Section cross-reference(s): 63

IT 60205-81-4, Ipratropium 99571-64-9, Oxitropium **185954-27-2** **185954-42-1**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase IV inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases)

IT **185954-27-2** **185954-42-1**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase IV inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases)

RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 06 Dec 2002
ACCESSION NUMBER: 2002:927247 CAPLUS Full-text
DOCUMENT NUMBER: 138:16606
TITLE: Combination of a PDE4 inhibitor and tiotropium for treating obstructive airways and other inflammatory diseases
INVENTOR(S): Yeadon, Michael; Armstrong, Roisin A.; Watson, John W.

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma KG, Germany
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096423	A2	20021205	WO 2002-EP5643	20020523
WO 2002096423	A3	20030206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2448363	A1	20021205	CA 2002-2448363	20020523
AU 2002314102	A1	20021209	AU 2002-314102	20020523
EP 1397135	A2	20040317	EP 2002-740638	20020523
EP 1397135	B1	20061206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004530705	T	20041007	JP 2002-592933	20020523
AT 347361	T	20061215	AT 2002-740638	20020523
US 2005107420	A1	20050519	US 2003-715177	20031117
PRIORITY APPLN. INFO.:			US 2001-293555P P	20010525
			US 2001-303845P P	20010709
			WO 2002-EP5643 W	20020523

OTHER SOURCE(S): MARPAT 138:16606
ED Entered STN: 06 Dec 2002
AB The present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising a PDEIV inhibitor that is effective in the treatment of the above diseases when administered by inhalation together with an anti-cholinergic agent selected from the group consisting of tiotropium and derivs. A method of treating the obstructive airways and other inflammatory diseases comprises administering by inhalation an effective amount of the above combination of agents and a package containing a composition for insertion into a device capable of simultaneous or sequential delivery of the pharmaceutical composition in the form of an aerosol or a dry powder dispersion to the mammal, where the device is a metered dose inhaler or a dry powder inhaler. The anti-cholinergic agent component may be tiotropium bromide. A package in the form of a pressurized, tetrafluoroethylene-coated aluminum canister for use in a metered dose inhaler is prepared which is sufficient to provide about 200 actuations of the inhaler, each actuation providing about 20 μg each active ingredient. The contents of each canister are as follows: 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, tiotropium bromide, dichlorodifluoromethane, dichlorotetrafluoroethane, trichloromonofluoromethane, and soya lecithin.
IC ICM A61K031-46
ICS A61K009-72; A61P011-06; A61P011-08; A61K031-46; A61K031-437
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT 136310-93-5 185954-10-3 185954-11-4
185954-14-7 185954-15-8 185954-19-2

185954-23-8 185954-26-1 185954-27-2
185954-28-3 185954-30-7 185954-33-0
185954-36-3 185954-39-6 185954-40-9
185954-42-1 185954-43-2 186691-13-4, Tiotropium 411207-31-3,
Tiotropium bromide monohydrate 477529-72-9 477725-30-7
477725-31-8 477725-32-9 477725-33-0 477725-35-2 477725-36-3
477725-37-4 477725-38-5 477725-39-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of PDE4 inhibitor and tiotropium for treating obstructive airways and inflammatory diseases)

IT 185954-10-3 185954-11-4 185954-14-7
185954-15-8 185954-19-2 185954-23-8
185954-26-1 185954-27-2 185954-28-3
185954-30-7 185954-33-0 185954-36-3
185954-39-6 185954-40-9 185954-42-1
477529-72-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of PDE4 inhibitor and tiotropium for treating obstructive airways and inflammatory diseases)

RN 185954-10-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-phenyl- (CA INDEX NAME)



RN 185954-11-4 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-3-(2-furanyl)-6,9-dihydro- (CA INDEX NAME)



RN 185954-14-7 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-methylphenyl)- (CA INDEX NAME)



RN 185954-15-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)



RN 185954-19-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 185954-23-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-pyridinyl)- (CA INDEX NAME)



RN 185954-26-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(4-pyridinyl)- (CA INDEX NAME)



RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-28-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-propyl- (CA INDEX NAME)



RN 185954-30-7 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-33-0 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3,9-dicyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-36-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-

6,9-dihydro-3-(1-methylcyclohexyl)- (CA INDEX NAME)



RN 185954-39-6 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-iodophenyl)- (9CI) (CA INDEX NAME)



RN 185954-40-9 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 477529-72-9 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(3-thienyl)- (CA INDEX NAME)



L4 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 25 Sep 2001
ACCESSION NUMBER: 2001:697570 CAPLUS Full-text
DOCUMENT NUMBER: 136:8039
TITLE: Process Research and Large-Scale Synthesis of a Novel 5,6-Dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine PDE-IV Inhibitor
AUTHOR(S): Urban, Frank J.; Anderson, Bruce G.; Orrill, Susan L.; Daniels, Peter J.
CORPORATE SOURCE: Chemical Research and Development Department, Pfizer Global Research and Development, Groton, CT, 06340, USA
SOURCE: Organic Process Research & Development (2001), 5(6), 575-580
CODEN: OPRDFK; ISSN: 1083-6160
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 25 Sep 2001
AB An efficient synthesis of the PDE IV inhibitor, 9H-cyclopentyl-7-ethyl-3-(thiophen-2-yl)-pyrazolo[3,4-c]-1,2,4-triazolo-5,6-dihydro-[4,3-a]pyridine 1 is described. Starting from com. available γ-caprolactone, the synthesis was carried out in 10 steps. Key transformations were the selective O-methylation of diketone, 3-hydroxy-1-(4-methoxybenzyl)-4- propionyl-5,6-dihydro-1H-pyridin-2-one, with di-Me sulfate and cesium carbonate in DMF, a one-pot pyrazole formation with subsequent acidic deprotection to provide lactam, 1-cyclopentyl-3-ethyl-1,4,5,6- tetrahydropyrazolo[3,4-c]pyridin-7-one, and finally the utilization of imidate, 1-cyclopentyl-7-ethoxy-3-ethyl-4,5-dihydro-1H-pyrazolo[3,4- c]pyridine for the introduction of the triazole moiety. This process avoided the use of harsh reaction conditions, undesirable reagents and overcame the environmental concerns in the original synthesis.
CC 45-4 (Industrial Organic Chemicals, Leather, Fats, and Waxes)
Section cross-reference(s): 15, 28
IT **185954-27-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(process research and large-scale synthesis of a novel 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine PDE-IV inhibitor)
IT **185954-27-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(process research and large-scale synthesis of a novel 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine PDE-IV inhibitor)
RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 05 Nov 2000
ACCESSION NUMBER: 2000:773960 CAPLUS Full-text
DOCUMENT NUMBER: 133:335234
TITLE: Preparation of 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes
INVENTOR(S): Urban, Frank John
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1048667	A1	20001102	EP 2000-302947	20000407
EP 1048667	B1	20031022		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2001039347	A1	20011108	US 2000-516549	20000301
US 6326495	B2	20011204		
AT 252582	T	20031115	AT 2000-302947	20000407
EP 1380585	A1	20040114	EP 2003-24166	20000407
EP 1380585	B1	20041110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PT 1048667	T	20040331	PT 2000-302947	20000407
ES 2207464	T3	20040601	ES 2000-302947	20000407
AT 282039	T	20041115	AT 2003-24166	20000407
PT 1380585	T	20050331	PT 2003-24166	20000407
ES 2232805	T3	20050601	ES 2003-3024166	20000407
IN 192746	A1	20040515	IN 2000-DE447	20000424
TW 256392	B	20060611	TW 2000-89107724	20000425
JP 2000344771	A	20001212	JP 2000-125351	20000426
JP 3510560	B2	20040329		
ZA 2000002057	A	20011026	ZA 2000-2057	20000426
TR 200001161	A2	20001221	TR 2000-1161	20000427
CA 2307080	A1	20001030	CA 2000-2307080	20000428
CA 2307080	C	20031223		
CN 1274724	A	20001129	CN 2000-108140	20000428
HU 200001700	A2	20010328	HU 2000-1700	20000428
RU 2189985	C2	20020927	RU 2000-111018	20000428
AU 761391	B2	20030605	AU 2000-30180	20000428
CN 1478779	A	20040303	CN 2003-147645	20000428

BR 2000002070	A	20001031	BR 2000-2070		20000502
HK 1031881	A1	20050204	HK 2001-102535		20010410
HK 1062678	A1	20060908	HK 2004-105520		20040727
PRIORITY APPLN. INFO.:			US 1999-131949P	P	19990430
			EP 2000-302947	A3	20000407

OTHER SOURCE(S): CASREACT 133:335234; MARPAT 133:335234
ED Entered STN: 05 Nov 2000
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = H, alkyl, alkoxy, etc.] were prepared by (a) subjecting a solventless reaction mixture of γ-caprolactone and p-methoxybenzylamine to heating, (b) reducing the resulting 4-hydroxyhexanoic acid 4-methoxybenzylamide, (c) acylating 6-(4-methoxybenzylamino)hexan-3-ol with Et oxalyl chloride, (f) oxidizing the resulting oxalamic acid Et ester II , (e) ring closing the oxalamide ketone III, (f) O-methylating the resulting 3-hydroxy-1-(4-methoxybenzyl)- 4-propionyl-5,6-dihydro-1H-pyridin-2-one, (g) treating 3-methoxy-1-(4-methoxybenzyl)-4-propionyl-5,6-dihydro-1H-pyridin-2-one with cyclopentylhydrazine, (h) deprotecting the pyrazolopyridinone IV, (i) esterifying the lactam V, (j) and treating the resulting imino ester (imidate) VI with a carboxylic hydrazide R1CONHNH2.

IC ICM C07D471-14
ICS C07D471-04
ICI C07D471-14, C07D249-00, C07D231-00, C07D221-00
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
IT **185954-27-2P 185954-42-1P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes)
IT **185954-27-2P 185954-42-1P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes)
RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 10 Feb 1997
ACCESSION NUMBER: 1997:94069 CAPLUS Full-text
DOCUMENT NUMBER: 126:104095
TITLE: Preparation of tricyclic 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridines as inhibitors of phosphodiesterase (PDE) Type IV and the production of tumor necrosis factor (TNF)
INVENTOR(S): Duplantier, Allen J.; Cooper, Kelvin
PATENT ASSIGNEE(S): Pfizer Inc., USA; Duplantier, Allen J.; Cooper, Kelvin
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9639408	A1	19961212	WO 1995-IB429	19950606
W: CA, FI, JP, MX, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2223624	A1	19961212	CA 1995-2223624	19950606
CA 2223624	C	20010220		
EP 837860	A1	19980429	EP 1995-918707	19950606
EP 837860	B1	20020320		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
JP 10510242	T	19981006	JP 1996-511176	19950606
JP 3107827	B2	20001113		
SK 282167	B6	20011106	SK 1996-718	19950606
AT 214700	T	20020415	AT 1995-918707	19950606
PT 837860	T	20020731	PT 1995-918707	19950606
ES 2172583	T3	20021001	ES 1995-918707	19950606
TW 460469	B	20011021	TW 1996-85105271	19960502
PL 184195	B1	20020930	PL 1996-314459	19960527
IL 118485	A	20000217	IL 1996-118485	19960530
IN 1996DE01159	A	20050311	IN 1996-DE1159	19960530
LV 11620	B	19970420	LV 1996-174	19960604
BR 9602627	A	19980901	BR 1996-2627	19960604
NO 9602320	A	19961209	NO 1996-2320	19960605
AU 9654773	A	19961219	AU 1996-54773	19960605
AU 694871	B2	19980730		
HU 9601541	A2	19970228	HU 1996-1541	19960605
ZA 9604649	A	19971205	ZA 1996-4649	19960605
KR 191972	B1	19990615	KR 1996-20169	19960605
CZ 287251	B6	20001011	CZ 1996-1626	19960605
RU 2161158	C2	20001227	RU 1996-111027	19960605

CN 1142499	A	19970212	CN 1996-107630		19960606
CN 1061044	B	20010124			
RO 115881	B1	20000728	RO 1996-1157		19960606
HR 960268	B1	20021231	HR 1996-268		19960606
AP 932	A	20010202	AP 1996-849		19960826
W: GM, BW, KE, MW, UG, ZM, ZW					
FI 9704434	A	19971205	FI 1997-4434		19971205
FI 114097	B1	20040813			
US 6004974	A	19991221	US 1998-973590		19980327
KR 225719	B1	19991015	KR 1998-44720		19981024
PRIORITY APPLN. INFO.:			CA 1995-2223624	A	19950606
			EP 1995-918707	A	19950606
			WO 1995-IB429	A	19950606
			HU 1996-1541	A	19960605
			KR 1996-20169	A	19960605

OTHER SOURCE(S): MARPAT 126:104095
ED Entered STN: 10 Feb 1997
GI



I

AB The title compds. [I; R1 = H, C1-6 alkyl, C1-6 alkoxy, etc.; R2, R3 = H, C1-14 alkyl, C2-14 alkenyl, etc.; R4, R5 = H, C1-6 alkyl, C1-6 alkoxy, etc.], useful in treating an inflammatory condition, asthma, arthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis as well as AIDS, septic shock and other diseases, such as cachexia, were prepared Thus, reaction of 1-cyclopentyl-4,5-dihydro- 3-ethyl-7-methylthio-1H-pyrazolo[3,4-c]pyridine with nicotinic acid hydrazide in pyridine afforded I [R1 = Et; R2 = 3-pyridyl; R3 = cyclopentyl; R4, R5 = H]. In general, compds. I are effective at 0.3-5 mg/kg/day.

IC ICM C07D471-14
ICS A61K031-435

ICI C07D471-14, C07D249-00, C07D231-00, C07D221-00

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT **185954-09-0P 185954-10-3P 185954-11-4P**
185954-12-5P 185954-13-6P 185954-14-7P
185954-15-8P 185954-16-9P 185954-17-0P
185954-18-1P 185954-19-2P 185954-20-5P
185954-21-6P 185954-22-7P 185954-23-8P
185954-24-9P 185954-25-0P 185954-26-1P
185954-27-2P 185954-28-3P 185954-29-4P
185954-30-7P 185954-31-8P 185954-33-0P
185954-34-1P 185954-36-3P 185954-37-4P
185954-39-6P 185954-40-9P 185954-42-1P
185954-43-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-

triazolo[4,3-
α]pyridines as inhibitors of phosphodiesterase (PDE) Type IV and the production of tumor necrosis factor (TNF))

IT 185954-09-0P 185954-10-3P 185954-11-4P
185954-12-5P 185954-13-6P 185954-14-7P
185954-15-8P 185954-16-9P 185954-17-0P
185954-18-1P 185954-19-2P 185954-20-5P
185954-21-6P 185954-22-7P 185954-23-8P
185954-24-9P 185954-25-0P 185954-26-1P
185954-27-2P 185954-28-3P 185954-29-4P
185954-30-7P 185954-31-8P 185954-33-0P
185954-34-1P 185954-36-3P 185954-37-4P
185954-39-6P 185954-40-9P 185954-42-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-
α]pyridines as inhibitors of phosphodiesterase (PDE) Type IV and the production of tumor necrosis factor (TNF))

RN 185954-09-0 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(3-pyridinyl)- (CA INDEX NAME)



RN 185954-10-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-phenyl- (CA INDEX NAME)



RN 185954-11-4 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-3-(2-furanyl)-6,9-dihydro- (CA INDEX NAME)



RN 185954-12-5 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(3-methoxyphenyl)- (CA INDEX NAME)



RN 185954-13-6 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(3-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 185954-14-7 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-methylphenyl)- (CA INDEX NAME)



RN 185954-15-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)



RN 185954-16-9 CAPLUS
CN Phenol, 4-(9-cyclopentyl-7-ethyl-6,9-dihydro-5H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 185954-17-0 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-(3-chloro-4-methyl-2-thienyl)-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-18-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 185954-19-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 185954-20-5 CAPLUS
CN Phenol, 3-(9-cyclopentyl-7-ethyl-6,9-dihydro-5H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 185954-21-6 CAPLUS
CN Phenol, 2-(9-cyclopentyl-7-ethyl-6,9-dihydro-5H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridin-3-yl)-6-methyl- (9CI) (CA INDEX NAME)



RN 185954-22-7 CAPLUS
CN Phenol, 2-(9-cyclopentyl-7-ethyl-6,9-dihydro-5H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 185954-23-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-pyridinyl)- (CA INDEX NAME)



RN 185954-24-9 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine-3-methanol, 9-cyclopentyl-7-ethyl-6,9-dihydro-α-phenyl- (9CI) (CA INDEX NAME)



RN 185954-25-0 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-[(3,4-dimethoxyphenyl)methyl]-7-ethyl-6,9-dihydro- (9CI) (CA INDEX NAME)



RN 185954-26-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(4-pyridinyl)- (CA INDEX NAME)



RN 185954-27-2 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- (CA INDEX NAME)



RN 185954-28-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-propyl- (CA INDEX NAME)



RN 185954-29-4 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-methyl- (CA INDEX NAME)



RN 185954-30-7 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-31-8 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-(3-chlorophenyl)-9-cyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-33-0 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3,9-dicyclopentyl-7-ethyl-6,9-dihydro- (CA INDEX NAME)



RN 185954-34-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 185954-36-3 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(1-methylcyclohexyl)- (CA INDEX NAME)



RN 185954-37-4 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 3-(2-chloro-3-pyridinyl)-9-cyclopentyl-7-ethyl-6,9-dihydro- (9CI) (CA INDEX NAME)



RN 185954-39-6 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-iodophenyl)- (9CI) (CA INDEX NAME)



RN 185954-40-9 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 185954-42-1 CAPLUS
CN 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-3-(1,1-dimethylethyl)-7-ethyl-6,9-dihydro- (CA INDEX NAME)



=>